BANGKOK, THAILAND - Media OutReach Newswire - 1 July 2026 - ICONSIAM, the global landmark and experiential destination on the banks of the Chao Phraya River, successfully concluded Pride Month 2026 with a historic celebration that captured worldwide attention and reinforced Thailand's position as a leading Pride-Friendly Destination. On the evening of 30 June 2026, ICONSIAM created an unprecedented spectacle with Thailand's first-ever Rainbow Drone and Fireworks Show, illuminating Bangkok's iconic riverfront and showcasing the nation's commitment to diversity, equality, and inclusion.
The historic finale drew overwhelming interest from both local and international visitors, who gathered along the Chao Phraya River to witness "Journey of Pride Spectrum" — Thailand's first-ever five-minute aerial display combining vibrant rainbow-themed drones and fireworks. Set against the stunning backdrop of Bangkok's most iconic riverfront destination, the spectacular performance transformed the night sky into a powerful symbol of unity, acceptance, and hope. Images and videos of the event were rapidly shared across social media platforms around the world, generating significant online engagement and further highlighting Bangkok's growing reputation as a welcoming global destination for LGBTQIA+ communities and travelers.
"Journey of Pride Spectrum" — Thailand's first five-minute rainbow drone and fireworks show.
The landmark celebration also served as a compelling demonstration of Thailand's readiness to host World Pride 2030. Through this extraordinary showcase of creativity, inclusivity, and cultural expression, ICONSIAM reinforced Bangkok's potential to welcome global audiences and host world-class international events that unite people from all walks of life.
Throughout the month of June, under the "UNITY OF PRIDE: DIVERSE SERIES, ONE COMMUNITY" campaign, ICONSIAM welcomed visitors with a series of immersive experiences that celebrated the vibrant spirit of Rainbow Culture, creating memorable moments and spreading positivity both on-site and across digital platforms.
The destination was transformed into a true Pride-Friendly Destination, featuring the spectacular Pride Rainbow Waterfall on the 6th floor, Asia's longest rainbow-themed dancing fountain show, and the dazzling ICONIC Rainbow Lighting installation created in collaboration with LightSource, illuminating the iconic façade at the building's pinnacle in vibrant rainbow hues. The month-long celebration was further enriched by a diverse lineup of signature events, including the A FAIR x UNITY OF PRIDE shopping festival, the exclusive Pride & Greet fan experience with artists from DOMUNDI, and the contemporary art exhibition "Colors of Pride: Unity in Diversity" by Queer Art Thailand on the M Floor. Together, these experiences powerfully championed the values of diversity, inclusion, and equality, reinforcing ICONSIAM's commitment to creating a welcoming space where every individual is celebrated.
ICONSIAM believes that diversity is a source of strength that enriches communities, inspires creativity, and brings people together. The overwhelming response to UNITY OF PRIDE and Thailand's first-ever Rainbow Drone and Fireworks Spectacular reflects the growing importance of creating inclusive spaces where everyone feels welcomed, respected, and celebrated. As a Global Experiential Destination, ICONSIAM remains committed to championing diversity, equality, and meaningful participation while creating extraordinary experiences that inspire visitors from around the world. Through collaborations with partners across the public and private sectors, ICONSIAM continues to support initiatives that strengthen Thailand's global profile, promote cultural exchange, and reinforce Bangkok's position as one of Asia's most dynamic, inclusive, and welcoming destinations, while contributing to Thailand's vision of becoming a global destination that embraces diversity and supporting the city's journey towards hosting World Pride 2030.
For more information, please visit www.iconsiam.com.
Hashtag: #ICONSIAM #UnityOfPride #RainbowFireworks #WorldPride2030 #BangkokPride #PrideMonth2026
The issuer is solely responsible for the content of this announcement.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
ICONSIAM Pride Month 2026
Transaction Valued at $122.5M Establishes 20,000-Liter US Biologics Drug Substance Manufacturing Platform, Covering Development through Commercial Supply
TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.
With the close of the transaction, Bora Group's biologics CDMO franchise, Bora Biologics, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites: Rockville, Maryland and San Diego, California, and one development facility in Zhubei, Taiwan.
"This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply," said Bobby Sheng, Chairman and CEO of Bora Group. "As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
With the addition of the Rockville facility, Bora Biologics supports more than 4 active commercial programs, with more than 120 completed GMP batches and supply into multiple global markets including the US, EU, Japan, Canada and the UK with fully integrated QC and analytical capabilities.
Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, with clean results at both sites. The combined platform has supported more than 33 biologics and 15 biosimilars, establishing a manufacturing base for biotech and pharmaceutical companies with reduced offshore dependency and domestically anchored infrastructure.
Bora Group intends to integrate its US drug substance (DS) capabilities with its existing sterile drug product (DP) capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution.
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
